February 7th, 2014 Opsumit, as monotherapy or in combination with approved PAH treatments (phosphodiesterase-5 inhibitors or inhaled prostanoids), is indicated for the treatment of idiopathic …
-
-
[[Whitepaper ]] Disruptive Innovation in Rare Disease Markets
-
Choosing the Right Channel Strategy for Specialty Product Success
-
[Whitepaper] Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies
-
[[whitepaper]] The New Reality: Maximizing Value in Rare Disease Launches
-
What’s New in Rare Cancer Research? (Spoiler Alert: A Lot!)
